2284-PUB: Overweight/Obesity in Young T1D Patients Is Differently Associated to First Degree Relatives’ History or Features According to Their Gender

Introduction: Obesity is increasing in T1D patients worldwide and is related to cardiovascular (CV) disease. Objective: To identify the background characteristics linked to overweight/obesity and CV risk factors during insulin treatment in T1D patients. Methods: We performed anthropometric, laboratory and genetic analysis - FTO rs9939609 and visfatin rs9770242 of young Brazilian T1D. This study was approved by the Ethic Committee. Results: From 181 T1D patients (age 23.6±5.5 y, diabetes duration 12.1±7.2 y, A1c 8.9±1.9%), 87 were female - 64.4% normal weight (NW), 26.4% overweight (OW) and 9.2% obese (OB) - and 94 male (77.7% NW, 14.9% OW and 7.4% OB). Male: OB were older (OB: 29.4±3.7 y vs. OW: 23.2±5.8 vs. NW: 22.5±5.3, p=0.01), had higher prevalence of blacks (57.1% vs. 7.1 vs. 7, p=0.01), higher triglycerides levels (180.3±140.2 mg/dL vs. 74.4±34.4 vs. 87±57.1, p=0.03), diastolic BP (85±8.4 mmHg vs. 78.9±9.2 vs. 73.4±9.6, p=0.009) and lower eGDR (5.4±1.9 mg/Kg/min vs. 6.8±1.9 vs. 7.9±1.7, p=0.003). Higher prevalence of AH (100% vs. 57.1 vs. 50.7, p=0.03) and early CV disease (28.6% vs. 7.1 vs. 2.7, p=0.02) in their first-degree relatives (FDR) were also found in OB. A1c, insulin dose (U/kg/day), diabetes duration, physical activity, high molecular weight (HMW) adiponectin, visfatin, FTO and visfatin genes polymorphisms were not different in NW and OW/OB. Female: We found no difference between groups in A1c, insulin dose, diabetes duration, physical activity, HMW adiponectin, visfatin or FTO and visfatin genes polymorphisms. OW and OB had lower eGDR (5.4±2.4 mg/Kg/min vs. 6.1±2.1 vs. 8±2.1, p=0.0002). OB women had FDR with obesity more frequently (62.5% vs. 47.8 vs. 25.5, p=0.03). Conclusion: FDR with obesity is a risk factor to OW/OB in female T1D as well as FDR with early CV disease or AH in male T1D. These specifics familiar background must be considered for early prevention of CV risk factors during natural history of T1D. Disclosure F. Valente: Consultant; Spouse/Partner; Sanofi Genzyme. Speaker’s Bureau; Self; AstraZeneca, Novo Nordisk Inc. T. Valente: None. S.A. Dib: None.